| Identification | Back Directory | [Name]
Tamsulosin hydrochloride | [CAS]
80223-99-0 | [Synonyms]
EC-617
Tamuzosin hydrochloride
Tamsulosin hydrochloride
Tamsulosinehydrochloride
dl-Tamsulosin hydrochloride
ac Tamsulosin Hydrochloride
RaceMic TaMsulosin Hydrochloride
5-[(2RS)-2-[[2-(2-Ethoxyphenoxy)eth
Racemic Tamsulosin Hydrochloride (50 mg)
Tamsulosin Impurity 12(Tamsulosin HCl Racemate)
5-[2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide hydrochloride
(-)-(R)-5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide hydrochloride
Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, monohydrochloride (9CI) | [Molecular Formula]
C20H29ClN2O5S | [MDL Number]
MFCD09954593 | [MOL File]
80223-99-0.mol | [Molecular Weight]
444.97 |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Uses]
Tamsulosin hydrochloride is a specific ;1-adrenoceptor antagonist. Used in the treatment of benign prostatic hypertrophy.
| [Clinical Use]
Treatment of benign prostatic hyperplasia | [Drug interactions]
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antifungals: concentration increased by
ketoconazole.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect, avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension. | [Metabolism]
Tamsulosin is metabolised slowly in the liver primarily
by the cytochrome P450 isoenzymes CYP2D6 and
CYP3A4; it is excreted mainly in the urine as metabolites
and some unchanged drug |
|
|